Key points

• Includes data from 35 studies from across the world
• The Magtrace® lymphatic tracer is superior to blue dye alone, and comparable to the standard dual-modality technique of blue dye with Tc

Key points

• Unlike blue dye, which reported cases of anaphylaxis, no significant adverse effects were recorded for the Magtrace® lymphatic tracer

Key points

• SN detection rates were 96.8% for standard technique versus 97.1% for the Magtrace® lymphatic tracer
• All seven studies favour the Magtrace® lymphatic tracer for successful retrieval of lymph nodes against standard technique – average of 1.9 per patient vs 1.8 respectively
• The Magtrace® lymphatic tracer reports significantly lower false negative rates to the standard technique

Key points

• Nodal detection rate for the Magtrace® lymphatic tracer was significantly higher (97.3%) than the radioisotope (91.8%)

Key points

• The nodal detection rate was higher for the Magtrace® lymphatic tracer
• It has the benefit of reducing hospital costs with more flexible scheduling

Key points

• A superior rate of detection was noted with the Magtrace® lymphatic tracer (98.3%) vs radioisotope (95.7%)
• The Magtrace® lymphatic tracer obtained 2.2 nodes on average per patient, compared to 1.9 for radioisotope

Key points

• High detection rate of 95% and average lymph node retrieval rate of 2 nodes per patient
• The magnetic technique has significant advantages in that it can replace the need for blue dye and can be visualised on MRI

Key points

• Magtrace® lymphatic tracer detection rate was 99.3%, the dual technique per patient detection rate was 98.6%
• Average number of nodes detected per patient with the Magtrace® lymphatic tracer was 2.4
• The Magtrace® lymphatic tracer offers greater scheduling flexibility

Key points

• Five clinical trials were included, with 1,683 SLN’s in 804 patients
• Magtrace® lymphatic tracer demonstrated statistical non-inferiority with standard tracers
• No anaphylaxis associated with the Magtrace® lymphatic tracer

Summary

A Meta-analysis showing Magtrace® lymphatic tracer non-inferiority versus ‘conventional techniques’ for SLNB in addition to reporting on a multicentre prospective trial

Key points

• SN detection rates were 97.1% for standard technique and 97.6% for the Magtrace® lymphatic tracer
• The Magtrace® lymphatic tracer was comparable to the standard techniques and also simplifies logistics
• The technique was easily adopted amongst surgeons experienced with the SLNB technique

Summary

The Sentimag® probe is a safe SLN identification method and has a low risk of complications

Key points

• Significant correlation was noted between number of nodes resected and post-operative complications
• Discoloration due to Magtrace® lymphatic tracer injection was noted in 15.5% of patients
• Discolouration reduced to 3.6% of patients at 30 months

Key points

• Magtrace® lymphatic tracer results were non-inferior to those of the standard dual technique
• The use of the Magtrace® lymphatic tracer can simplify logistics and improve performance, e.g. adding the potential to inject the Magtrace® lymphatic tracer days before the operation

Key points

• The largest cohort of Magtrace® lymphatic tracer-only use for SLNB, in an Asian population
• The Magtrace® lymphatic tracer provided a 98.8% per patient detection rate
• On site savings of $22,300 per year when using the Magtrace® lymphatic tracer compared to a radiotracer

Key points

• No Magseed® marker migration was noted and low tumour resection volumes were documented (CRR - 1.49)
• Peritumoral injection of the Magtrace® lymphatic tracer was utilised and all SLNB’s were successful
• Clinicians reported the method was easier than hook-wire localisation
• Hospital scheduling was improved

Key points

• All lesions were successfully excised with tumour-free margins
• SLNB was successful in all patients
• The Magtrace® lymphatic tracer was injected subareolar pre or post operatively
• No interference between the Magseed® marker and Magtrace® lymphatic tracer signals was noted

Key points

• 78.3% of patients were able to avoid an unnecessary SLNB
• All delayed SLNBs were successful
• Costs were reduced by 24.5% in women without IBC

Summary

This study evaluates the feasibility of using MRI following the administration of the Magtrace® lymphatic tracer for pre-operative localization of SLN’s and its potential for non-invasive identification of lymph node metastases

Key points

• Magtrace® lymphatic tracer MRI successfully identified SLNs in 10 of 11 patients
• Magtrace® lymphatic tracer MRI is a feasible technique for pre-operative localisation of SLNs and, in combination with the Sentimag® probe, provides an entirely radioisotope-free technique for SLNB

Key points

• Intratumoral injection of Magtrace® lymphatic tracer was done pre-operatively
• SLNB was successful with Magtrace® lymphatic tracer plus blue dye equivalent to the standard technique
• Magtrace® lymphatic tracer lesion localisation in a SNOLL type procedure is feasible and also enables SLNB